The results possibly reflect clinical heterogeneity, gene-environment interactions, or secondary disease factors, and suggest that important information may be overlooked when only assessing mean differences between patients and healthy individuals.
Read about the study in this JAMA Psychiatry editorial comment: Toward high reproducibility and accountable heterogeneity in schizophrenia research
Reference
Alnæs D, Kaufmann T, van der Meer D, Córdova-Palomera A, Rokicki J, Moberget T, Bettella F, Agartz I, Barch DM, Bertolino A, Brandt CL, Cervenka S, Djurovic S, Doan NT, Eisenacher S, Fatouros-Bergman H, Flyckt L, Di Giorgio A, Haatveit B, Jönsson EG, Kirsch P, Lund MJ, Meyer-Lindenberg A, Pergola G, Schwarz E, Smeland OB, Quarto T, Zink M, Andreassen OA, Westlye LT; Karolinska Schizophrenia Project Consortium. Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk. JAMA Psychiatry. 2019 Apr 10. doi: 10.1001/jamapsychiatry.2019.0257.